Johnson & Johnson (JNJ)vsRein Therapeutics Inc (RNTX)
JNJ
Johnson & Johnson
$276.32
+3.81%
HEALTHCARE · Cap: $657.68B
RNTX
Rein Therapeutics Inc
$0.66
-1.32%
HEALTHCARE · Cap: $50.31M
Smart Verdict
WallStSmart Research — data-driven comparison
JNJ leads profitability with a 16.2% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 54/100 (C-).
JNJ
Buy54
out of 100
Grade: C-
RNTX
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-89.3%
Fair Value
$144.28
Current Price
$276.32
$132.04 premium
Intrinsic value data unavailable for RNTX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.7%
Generating 6.4B in free cash flow
No standout strengths identified
Areas to Watch
Trading at 8.2x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.7%.
Bull Case : RNTX
RNTX has a balanced fundamental profile.
Bear Case : JNJ
The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 41.5x leaves little room for execution misses.
Bear Case : RNTX
The primary concerns for RNTX are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
JNJ profiles as a mature stock while RNTX is a value play — different risk/reward profiles.
RNTX carries more volatility with a beta of 1.35 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (54/100 vs 23/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Rein Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rein Therapeutics Inc (RNTX) is a forward-thinking biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative disorders through its proprietary technology platform that merges advanced neuroscience with drug development. With a robust pipeline aimed at addressing critical unmet medical needs, the company is positioned at the forefront of a rapidly evolving therapeutic landscape. Led by an experienced management team with a proven track record in the industry, Rein Therapeutics offers institutional investors a compelling opportunity to engage with transformative healthcare solutions that have the potential to drive significant patient impact and market growth.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?